All In Biotech

Drug Trial Radar · NCT01588171

Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum

Bemiparin Versus Enoxaparin as Thromboprophylaxis Following Vaginal and Abdominal Deliveries: A Prospective Clinical Trial

Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

7,020

Actual

Start

May 2012

Primary completion

Oct 2013

Study completion Nov 2013

Sponsor

Lead sponsor
Hawler Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 30, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Prevention
Who can join
Female only, from 15 years, up to 48 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The use of a new generation low molecular weight heparin (Bemiparin)and the well known LMWH (Enoxaparin) after Caesarean sections and vaginal deliveries in a risky group patients for venous thrombosis.

Conditions

  • Venous Thromboembolic Diseases

Interventions

  • BemiparinDrug

    Bemiparin sodium 3,500 IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group; subcutaneously 6 hours after delivery(vaginal and Caesarean)and then daily for up to 7 days.

  • EnoxaparinDrug

    Enoxaparin sodium 40mg (equivalent to 4,000 IU anti-Xa activity) in 0.4ml water for injection will be administered subcutaneously 6 hours after the delivery( vaginal or abdominal)then daily up to 7 days post partum, for Enoxaparin group of patients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Venous thromboembolismTime frame: 40 days after delivery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hawler medical university

    Erbil, Kurdistan Region, Iraq

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.